(1) 癌症相关新型靶标及其小分子抑制剂的研究
(2) 小分子的结构优化与构效关系研究
(3) 小分子成药性改造以及细胞和动物水平的生物学评估

专利转化
以主要参与人身份参与新型CDK4/6-DYRK2双靶点抑制剂，专利转让，江苏天士力帝益药业有限公司，12000万元，2021年11月。

1.Kuang, W.B. #; Wang, X. #; Ding, J.Y. #; Li, J.X.; Ji, M.H.; Chen, W.J.; Wang, L.P.; Yang, P.* PTPN2, A Key Predictor of Prognosis for Pancreatic Adenocarcinoma, Significantly Regulates Cell Cycles, Apoptosis, and Metastasis. Front Immunol, 2022, 13: 805311. (IF: 8.786)
2.Kuang, W.B. #; Zhang, H.L. #; Wang, X.; Yang, P.* Overcoming Mycobacterium tuberculosis through small molecule inhibitors to break down cell wall synthesis. Acta Pharm Sin B, 2022, DOI: https://doi.org/10.1016/j.apsb.2022.04.014. (IF: 14.903)
3.Yuan, K. #; Li, Z.X. #; Kuang, W.B. #; Wang, X. #; Ji, M.H.; Chen, W.J.; Ding, J.Y.; Li, J.X.; Min, W.J.; Sun, C.L.; Ye, X.Q.; Lu, M.L.; Wang, L.P.; Ge, H.X.; Jiang, Y.Z.*; Hao, H.P.*; Xiao, Y.B.*; Yang, P.* Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) with a highly selective inhibitor for the treatment of prostate cancer. Nat Commun, 2022, 13: 2903. (IF: 17.694)
4.Yuan, K. #; Kuang, W.B. #; Chen, W.J. #; Ji, M.H.; Min, W.J.; Zhu, Y.S.; Hou, Y.; Wang, X.; Li, J.X.; Wang, L.P.; Yang, P.* Discovery of novel and orally bioavailable CDK4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma. Eur J Med Chem, 2022, 228: 114024. (IF: 7.088)
5.Wang, X. #*; Kuang, W.B. #; Ding, J.Y. #; Li, J.X.; Ji, M.H.; Chen, W.J.; Shen H.; Shi Z.Y.; Wang D.W.; Wang, L.P.; Yang, P.* Systematic identification of the RNA-binding protein STAU2 as a key regulator of pancreatic adenocarcinoma. Cancers. 2022. Accept. (IF: 6.575)
6.Hou, Y.; Kuang, W.B.; Min, W.J.; Liu, Z.W.; Zhang, F.; Yuan, K.; Wang, X.; Sun, C.L.; Cheng, H.; Wang, L.P.; Xiao, Y.B.; Pu, S.B.*; Xin, G.Z. *; Yang, P.* Design, Synthesis, and Biological Evaluation of Icaritin Derivatives as Novel Putative DEPTOR Inhibitors for Multiple Myeloma Treatment. J Med Chem. 2021, 64(20):14942-14954. (IF: 8.038)
7.Kuang, W.B. #; Huang, R.Z. #; Qin, J.L.; Lu, X.; Qin, Q.P.; Zou, B.Q.; Chen, Z.F.*; Liang, H.*; Zhang, Y.* Design, synthesis and pharmacological evaluation of new 3-(1Hbenzimidazol-2-yl) quinolin-2(1H)-one derivatives as potential antitumor agents. Eur J Med Chem, 2018, 157, 139-150. (IF: 7.088)
8.Kuang, W.B.; Huang, R.Z.; Fang, Y.L.; Liang, G.B.; Yang, C.H.; Ma, X.L.*; Zhang, Y.* Design, synthesis and pharmacological evaluation of novel 2-chloro-3-(1H-benzo[d]imidazol-2-yl) quinoline derivatives as antitumor agents: in vitro and in vivo antitumor activity, cell cycle arrest and apoptotic response. RSC Adv., 2018, 8, 24376. (IF: 4.036)
9.Yu, Y.C. #; Kuang, W.B. #; Huang, R.Z.; Fang, Y.L.; Zhang, Y.*, Chen, Z.F.*; Ma, X.L.* Design, synthesis and pharmacological evaluation of new 2-oxo-quinoline derivatives containing α-aminophosphonates as potential antitumor agents. Med. Chem. Commun., 2017, 8, 1158. (IF: 5.121)